These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 36263140)

  • 1. Comprehensive analysis of cuproptosis in immune response and prognosis of osteosarcoma.
    Li M; Song Q; Bai Y; Hua F; Wu T; Liu J
    Front Pharmacol; 2022; 13():992431. PubMed ID: 36263140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma.
    Wang B; Song Q; Wei Y; Wu X; Han T; Bu H; Tang S; Qian J; Shao P
    Front Immunol; 2022; 13():948042. PubMed ID: 36275737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer.
    Song S; Zhang M; Xie P; Wang S; Wang Y
    Front Immunol; 2022; 13():978909. PubMed ID: 36341328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
    Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
    Front Immunol; 2022; 13():933973. PubMed ID: 36045691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma.
    Cai Z; He Y; Yu Z; Hu J; Xiao Z; Zu X; Li Z; Li H
    Front Immunol; 2022; 13():933241. PubMed ID: 36211378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive exploration of the involvement of cuproptosis in tumorigenesis and progression of neuroblastoma.
    Zhou R; Huang D; Fu W; Shu F
    BMC Genomics; 2023 Nov; 24(1):715. PubMed ID: 38012558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cuproptosis signature and PLCD3 predicts immune infiltration and drug responses in osteosarcoma.
    Hu H; Yin Y; Jiang B; Feng Z; Cai T; Wu S
    Front Oncol; 2023; 13():1156455. PubMed ID: 37007130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of a cuproptosis-related lncRNA signature for predicting prognosis and immune landscape in osteosarcoma patients.
    Ni S; Hong J; Li W; Ye M; Li J
    Cancer Med; 2023 Feb; 12(4):5009-5024. PubMed ID: 36129020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction and validation of a novel cuproptosis-mitochondrion prognostic model related with tumor immunity in osteosarcoma.
    Feng J; Wang J; Xu Y; Lu F; Zhang J; Han X; Zhang C; Wang G
    PLoS One; 2023; 18(7):e0288180. PubMed ID: 37405988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of cuproptosis-related patterns and construction of a scoring system for predicting prognosis, tumor microenvironment-infiltration characteristics, and immunotherapy efficacy in breast cancer.
    Li W; Zhang X; Chen Y; Pang D
    Front Oncol; 2022; 12():966511. PubMed ID: 36212436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cuproptosis-related signature predicts prognosis and indicates immune microenvironment in breast cancer.
    Li J; Wu F; Li C; Sun S; Feng C; Wu H; Chen X; Wang W; Zhang Y; Liu M; Liu X; Cai Y; Jia Y; Qiao H; Zhang Y; Zhang S
    Front Genet; 2022; 13():977322. PubMed ID: 36226193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel cuproptosis-related molecular pattern and its tumor microenvironment characterization in colorectal cancer.
    Zhu Z; Zhao Q; Song W; Weng J; Li S; Guo T; Zhu C; Xu Y
    Front Immunol; 2022; 13():940774. PubMed ID: 36248908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of cuproptosis-related subtypes and the development of a prognostic model in glioma.
    Wu Z; Li W; Zhu H; Li X; Zhou Y; Chen Q; Huang H; Zhang W; Jiang X; Ren C
    Front Genet; 2023; 14():1124439. PubMed ID: 36936439
    [No Abstract]   [Full Text] [Related]  

  • 14. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.
    Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P
    Front Immunol; 2022; 13():919231. PubMed ID: 35967366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
    Xu M; Mu J; Wang J; Zhou Q; Wang J
    Front Oncol; 2022; 12():961213. PubMed ID: 35965536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients.
    Jiang ZR; Yang LH; Jin LZ; Yi LM; Bing PP; Zhou J; Yang JS
    Front Oncol; 2022; 12():988680. PubMed ID: 36203428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revealing prognostic and tumor microenvironment characteristics of cuproptosis in bladder cancer by genomic analysis.
    Zhang S; Yu S; Duan H; Xia W; Wang C; Shen H
    Front Genet; 2022; 13():997573. PubMed ID: 36263417
    [No Abstract]   [Full Text] [Related]  

  • 18. Development and validation of a cuproptosis-related lncRNA model correlated to the cancer-associated fibroblasts enable the prediction prognosis of patients with osteosarcoma.
    Wang X; Xie C; Lin L
    J Bone Oncol; 2023 Feb; 38():100463. PubMed ID: 36569351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Cuproptosis-Related Subtypes, Establishment of a Prognostic Signature and Characterization of the Tumor Microenvironment in Gastric Cancer.
    Li J; Kong C; Song W; Fu T
    Int J Gen Med; 2023; 16():1631-1652. PubMed ID: 37168531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cuproptosis-Related Long Noncoding RNA Signature Predicts Prognosis and Tumour Immune Analysis in Osteosarcoma.
    Jiang J; Chu D; Lai X; Liu L; Tao J
    Comput Math Methods Med; 2022; 2022():6314182. PubMed ID: 36388161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.